---
title: "Drug developer Generate Biomedicines raises $400 million in US IPO"
description: "Feb 26 (Reuters) - Drug developer Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares at $16 each."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277123859.md"
published_at: "2026-02-27T01:09:31.000Z"
---

# Drug developer Generate Biomedicines raises $400 million in US IPO

> Feb 26 (Reuters) - Drug developer Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares at $16 each.

Feb 26 (Reuters) - Drug developer Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares at $16 each.

### Related Stocks

- [NNNN.US - Anbio Biotechnology](https://longbridge.com/en/quote/NNNN.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [PMCB.US - PharmaCyte Biotech](https://longbridge.com/en/quote/PMCB.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Alumis 在奥本海默医疗保健会议上公布了第三阶段银屑病研究的详细信息，并计划在下半年提交新药申请（NDA） | Alumis（纳斯达克代码：ALMS）高管在 Oppenheimer 医疗会议上展示了 envudeucitinib 的第三阶段银屑病结果，计划在下半年提交新药申请（NDA）。该药物达到了 74% 的 PASI 75 反应率，并在生活质量方 | [Link](https://longbridge.com/en/news/277123919.md) |
| Advisor OS LLC 增加了对麦克森公司（McKesson Corporation）股票的持有量 | Advisor OS LLC 在第三季度将其在麦克森公司（NYSE:MCK）的持股增加了 221.4%，在收购了 1,508 股后，现持有 2,189 股。这些持股的价值达到了 1,691,000 美元。其他机构投资者也调整了他们的持股，I | [Link](https://longbridge.com/en/news/277003609.md) |
| Delcath 第四季度收入增长 37%，超过了预期 | Delcath Systems 报告第四季度收入增长 37%，达到 2073 万美元，超出分析师预期。尽管出现净亏损，公司实现了正的调整后 EBITDA，并在回购计划下回购了股份。展望未来，Delcath 预计到 2026 年收入将至少达到 | [Link](https://longbridge.com/en/news/277046688.md) |
| Tevogen 因计划收购数字健康公司 Sciometrix 的多数股权而股价上涨 | 药物开发公司 Tevogen 的股价在盘前交易中上涨 13.7%，至 33 美分。该公司签署了一份意向书，计划收购 Sciometrix 的多数股权；如果交易达成，Tevogen 将获得 Clinicus 数字护理平台和远程监测工具的使用权 | [Link](https://longbridge.com/en/news/277058905.md) |
| 分析师对 Kymera Therapeutics 未来的预期 | 22 位分析师对 Kymera Therapeutics (NASDAQ:KYMR) 提出了不同的看法，最近的评级显示出看涨和看跌情绪的混合。12 个月的平均目标价为 123.41 美元，比之前的目标价上涨了 40.38%。分析师们调整了他 | [Link](https://longbridge.com/en/news/277092422.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.